BiotechTube

DSXS topical product

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Scalp Psoriasis

Conditions

Scalp Psoriasis

Trial Timeline

Jul 11, 2016 → Jan 2, 2018

NCT ID
NCT02933502

About DSXS topical product

DSXS topical product is a phase 2 stage product being developed by Sun Pharmaceutical for Scalp Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT02933502. Target conditions include Scalp Psoriasis.

What happened to similar drugs?

0 of 6 similar drugs in Scalp Psoriasis were approved

Approved (0) Terminated (0) Active (6)
🔄PART 1: Double-blind Placebo-controlled + PART 2: Double-blind Active Treatment ExtensionSun PharmaceuticalPhase 3
🔄DSXS + PlaceboSun PharmaceuticalPhase 3
🔄DSXS topical + Vehicle topicalSun PharmaceuticalPhase 3
🔄Calcipotriene/Betamethasone Dipropionate + Taclonex® + PlaceboGlenmark PharmaceuticalsPhase 3
🔄Secukinumab 300 mg + PlaceboNovartisPhase 3
🔄Roflumilast Foam 0.3% + Vehicle FoamArcutis BiotherapeuticsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT02933502Phase 2Completed
NCT02933528Phase 2Completed

Competing Products

7 competing products in Scalp Psoriasis

See all competitors
ProductCompanyStageHype Score
PART 1: Double-blind Placebo-controlled + PART 2: Double-blind Active Treatment ExtensionSun PharmaceuticalPhase 3
40
DSXS + PlaceboSun PharmaceuticalPhase 3
40
DSXS topical + Vehicle topicalSun PharmaceuticalPhase 3
40
Betamethasone Scalp Suspension 0.064%;0.0005% + Taclonex® + Placebo topical suspensionSun PharmaceuticalPhase 1
29
Calcipotriene/Betamethasone Dipropionate + Taclonex® + PlaceboGlenmark PharmaceuticalsPhase 3
40
Secukinumab 300 mg + PlaceboNovartisPhase 3
40
Roflumilast Foam 0.3% + Vehicle FoamArcutis BiotherapeuticsPhase 3
34